TransTech Pharma, Inc. Release: TTP054, a Novel, Orally Active Drug for Glucose Control, Progresses towards Completion of a Phase 2 Proof-of-Concept Clinical Trial in Type 2 Diabetics

HIGH POINT, N.C.--(BUSINESS WIRE)--TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents. TTP054 acts as an agonist of the glucagon-like peptide 1 receptor (GLP1r).